 Jose Banchs
Concepts (224)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Echocardiography | 14 | 2020 | 629 | 3.990 |
Why?
| | Heart Diseases | 11 | 2020 | 372 | 2.750 |
Why?
| | Neoplasms | 20 | 2020 | 1963 | 2.520 |
Why?
| | Echocardiography, Transesophageal | 5 | 2019 | 134 | 1.490 |
Why?
| | Ventricular Function, Left | 6 | 2020 | 454 | 1.370 |
Why?
| | Heart Ventricles | 6 | 2018 | 723 | 1.340 |
Why?
| | Ventricular Dysfunction, Left | 6 | 2020 | 379 | 1.240 |
Why?
| | Heart Neoplasms | 3 | 2018 | 51 | 1.240 |
Why?
| | Cardiovascular Diseases | 7 | 2020 | 1616 | 1.170 |
Why?
| | Anthracyclines | 4 | 2019 | 30 | 1.150 |
Why?
| | Antineoplastic Agents | 10 | 2019 | 2040 | 1.110 |
Why?
| | Medical Oncology | 5 | 2020 | 168 | 0.920 |
Why?
| | Cardiology | 4 | 2020 | 286 | 0.920 |
Why?
| | Stroke Volume | 6 | 2020 | 496 | 0.900 |
Why?
| | Heart Function Tests | 2 | 2019 | 77 | 0.830 |
Why?
| | Thrombosis | 2 | 2018 | 244 | 0.780 |
Why?
| | Practice Patterns, Nurses' | 1 | 2018 | 15 | 0.780 |
Why?
| | Osteosarcoma | 1 | 2019 | 76 | 0.760 |
Why?
| | Sarcoma | 2 | 2018 | 119 | 0.710 |
Why?
| | Thrombocytopenia | 1 | 2019 | 175 | 0.710 |
Why?
| | Tachycardia, Sinus | 1 | 2016 | 2 | 0.700 |
Why?
| | Diagnostic Imaging | 3 | 2018 | 273 | 0.680 |
Why?
| | Pericardial Effusion | 4 | 2019 | 17 | 0.680 |
Why?
| | Cardiomyopathies | 2 | 2016 | 282 | 0.650 |
Why?
| | Echocardiography, Three-Dimensional | 2 | 2018 | 74 | 0.620 |
Why?
| | Education, Medical, Continuing | 1 | 2016 | 136 | 0.620 |
Why?
| | Recovery of Function | 2 | 2016 | 590 | 0.620 |
Why?
| | Takotsubo Cardiomyopathy | 1 | 2015 | 4 | 0.610 |
Why?
| | Pericarditis | 1 | 2014 | 15 | 0.600 |
Why?
| | Fibroma | 1 | 2014 | 13 | 0.600 |
Why?
| | Rural Population | 1 | 2018 | 444 | 0.590 |
Why?
| | Aortic Aneurysm | 1 | 2014 | 55 | 0.570 |
Why?
| | Radiation Injuries | 1 | 2015 | 123 | 0.550 |
Why?
| | Radiotherapy | 1 | 2015 | 203 | 0.540 |
Why?
| | Endocarditis | 1 | 2012 | 34 | 0.510 |
Why?
| | Cardiovascular Infections | 1 | 2012 | 3 | 0.500 |
Why?
| | Multimodal Imaging | 4 | 2018 | 117 | 0.500 |
Why?
| | Vascular Diseases | 1 | 2015 | 220 | 0.500 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2014 | 190 | 0.500 |
Why?
| | Tongue Neoplasms | 1 | 2012 | 18 | 0.490 |
Why?
| | Tracheoesophageal Fistula | 1 | 2011 | 26 | 0.480 |
Why?
| | Cardiotoxicity | 5 | 2020 | 20 | 0.480 |
Why?
| | Cardiac Tamponade | 3 | 2016 | 17 | 0.480 |
Why?
| | Myocarditis | 1 | 2012 | 85 | 0.470 |
Why?
| | Mass Screening | 1 | 2018 | 991 | 0.460 |
Why?
| | Humans | 51 | 2020 | 108073 | 0.450 |
Why?
| | Fluoroscopy | 1 | 2011 | 140 | 0.450 |
Why?
| | Radiography, Interventional | 1 | 2011 | 106 | 0.440 |
Why?
| | Ultrasonography, Interventional | 1 | 2011 | 130 | 0.440 |
Why?
| | Trastuzumab | 5 | 2016 | 90 | 0.410 |
Why?
| | Quality Improvement | 1 | 2016 | 865 | 0.400 |
Why?
| | Middle Aged | 20 | 2019 | 28290 | 0.370 |
Why?
| | Stents | 1 | 2011 | 392 | 0.370 |
Why?
| | Female | 29 | 2019 | 61236 | 0.370 |
Why?
| | Echocardiography, Doppler, Color | 3 | 2015 | 47 | 0.360 |
Why?
| | Male | 26 | 2019 | 59744 | 0.360 |
Why?
| | Heart | 3 | 2018 | 679 | 0.360 |
Why?
| | Early Diagnosis | 3 | 2018 | 226 | 0.350 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2012 | 537 | 0.340 |
Why?
| | Breast Neoplasms | 5 | 2015 | 1855 | 0.330 |
Why?
| | Esophageal Neoplasms | 2 | 2020 | 225 | 0.310 |
Why?
| | Heart Conduction System | 2 | 2015 | 91 | 0.300 |
Why?
| | Troponin I | 3 | 2015 | 78 | 0.290 |
Why?
| | Prognosis | 7 | 2019 | 3402 | 0.270 |
Why?
| | Lung Neoplasms | 4 | 2020 | 2148 | 0.260 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2019 | 1360 | 0.260 |
Why?
| | Fatal Outcome | 2 | 2015 | 309 | 0.250 |
Why?
| | Electrocardiography | 2 | 2015 | 659 | 0.240 |
Why?
| | Predictive Value of Tests | 7 | 2018 | 1983 | 0.230 |
Why?
| | Radiation, Ionizing | 1 | 2020 | 58 | 0.220 |
Why?
| | Atrial Fibrillation | 2 | 2015 | 329 | 0.220 |
Why?
| | Ultrasonography | 3 | 2015 | 751 | 0.220 |
Why?
| | Biomarkers | 6 | 2016 | 3311 | 0.210 |
Why?
| | Retrospective Studies | 10 | 2019 | 10506 | 0.210 |
Why?
| | Adult | 13 | 2019 | 31195 | 0.200 |
Why?
| | Pericardiocentesis | 1 | 2019 | 13 | 0.200 |
Why?
| | Erdheim-Chester Disease | 1 | 2018 | 1 | 0.200 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2020 | 935 | 0.200 |
Why?
| | Texas | 3 | 2019 | 182 | 0.200 |
Why?
| | Systole | 2 | 2016 | 195 | 0.200 |
Why?
| | Myxoma | 1 | 2018 | 10 | 0.200 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2020 | 162 | 0.200 |
Why?
| | Cardiac Imaging Techniques | 1 | 2018 | 19 | 0.200 |
Why?
| | Coronary Artery Disease | 2 | 2015 | 668 | 0.190 |
Why?
| | Aged | 11 | 2018 | 19533 | 0.180 |
Why?
| | Carcinoid Heart Disease | 1 | 2017 | 1 | 0.180 |
Why?
| | Echocardiography, Doppler | 1 | 2018 | 129 | 0.180 |
Why?
| | Reproducibility of Results | 3 | 2016 | 2806 | 0.180 |
Why?
| | Risk Factors | 9 | 2020 | 8712 | 0.180 |
Why?
| | Doxorubicin | 2 | 2015 | 304 | 0.170 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 141 | 0.170 |
Why?
| | Academies and Institutes | 1 | 2016 | 30 | 0.170 |
Why?
| | Multiple Myeloma | 1 | 2018 | 123 | 0.170 |
Why?
| | Pericarditis, Constrictive | 1 | 2016 | 8 | 0.170 |
Why?
| | Oligopeptides | 1 | 2018 | 256 | 0.160 |
Why?
| | Cardiotoxins | 1 | 2015 | 5 | 0.160 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2015 | 605 | 0.160 |
Why?
| | Withholding Treatment | 1 | 2016 | 66 | 0.160 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 255 | 0.160 |
Why?
| | Thrombolytic Therapy | 1 | 2016 | 112 | 0.150 |
Why?
| | Follow-Up Studies | 4 | 2019 | 4794 | 0.150 |
Why?
| | Cardiotonic Agents | 1 | 2016 | 142 | 0.150 |
Why?
| | Myocardial Ischemia | 1 | 2018 | 338 | 0.150 |
Why?
| | Ventricular Dysfunction | 1 | 2015 | 18 | 0.150 |
Why?
| | Cefazolin | 1 | 2014 | 9 | 0.150 |
Why?
| | ROC Curve | 1 | 2016 | 481 | 0.150 |
Why?
| | Pulmonary Surgical Procedures | 1 | 2014 | 9 | 0.150 |
Why?
| | Daptomycin | 1 | 2014 | 16 | 0.150 |
Why?
| | Pericardium | 1 | 2015 | 58 | 0.150 |
Why?
| | Carotid Artery Diseases | 1 | 2015 | 63 | 0.150 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2015 | 301 | 0.140 |
Why?
| | Comorbidity | 3 | 2019 | 1565 | 0.140 |
Why?
| | Pulmonary Embolism | 1 | 2016 | 175 | 0.140 |
Why?
| | Dexmedetomidine | 1 | 2014 | 66 | 0.140 |
Why?
| | Amyloidosis | 1 | 2014 | 43 | 0.140 |
Why?
| | Heart Failure | 2 | 2016 | 1788 | 0.140 |
Why?
| | Postoperative Complications | 2 | 2015 | 2082 | 0.130 |
Why?
| | Preoperative Care | 2 | 2015 | 357 | 0.130 |
Why?
| | Hodgkin Disease | 1 | 2015 | 116 | 0.130 |
Why?
| | Heart Valve Prosthesis | 1 | 2014 | 128 | 0.130 |
Why?
| | Peroxidase | 1 | 2013 | 209 | 0.130 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2016 | 220 | 0.130 |
Why?
| | Chemoradiotherapy | 1 | 2014 | 200 | 0.130 |
Why?
| | Decision Trees | 1 | 2012 | 76 | 0.130 |
Why?
| | Coronary Vessels | 1 | 2015 | 263 | 0.130 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2013 | 146 | 0.130 |
Why?
| | Myocardium | 1 | 2018 | 1087 | 0.120 |
Why?
| | Endocarditis, Bacterial | 1 | 2012 | 31 | 0.120 |
Why?
| | Heart Arrest | 1 | 2016 | 324 | 0.120 |
Why?
| | Radiopharmaceuticals | 1 | 2013 | 212 | 0.120 |
Why?
| | Antibiotic Prophylaxis | 1 | 2012 | 96 | 0.120 |
Why?
| | Young Adult | 3 | 2019 | 10635 | 0.120 |
Why?
| | Positron-Emission Tomography | 1 | 2013 | 305 | 0.120 |
Why?
| | Cardiac Catheterization | 1 | 2015 | 536 | 0.110 |
Why?
| | Aortic Valve | 1 | 2014 | 412 | 0.110 |
Why?
| | Prosthesis Implantation | 1 | 2011 | 121 | 0.110 |
Why?
| | Radiosurgery | 1 | 2013 | 362 | 0.100 |
Why?
| | Combined Modality Therapy | 3 | 2018 | 1201 | 0.100 |
Why?
| | Risk Assessment | 3 | 2018 | 3073 | 0.100 |
Why?
| | Anti-Inflammatory Agents | 1 | 2012 | 441 | 0.100 |
Why?
| | Survival Rate | 3 | 2019 | 1781 | 0.090 |
Why?
| | Sensitivity and Specificity | 2 | 2011 | 1939 | 0.090 |
Why?
| | Treatment Outcome | 4 | 2018 | 8857 | 0.090 |
Why?
| | Aged, 80 and over | 4 | 2015 | 6648 | 0.090 |
Why?
| | Myocardial Infarction | 1 | 2015 | 1073 | 0.090 |
Why?
| | Incidence | 3 | 2020 | 2352 | 0.090 |
Why?
| | Antiviral Agents | 1 | 2012 | 610 | 0.080 |
Why?
| | Palliative Care | 1 | 2012 | 582 | 0.080 |
Why?
| | Prevalence | 1 | 2011 | 2287 | 0.070 |
Why?
| | Natriuretic Peptide, Brain | 2 | 2015 | 89 | 0.070 |
Why?
| | Anti-Bacterial Agents | 1 | 2012 | 1250 | 0.070 |
Why?
| | Taxoids | 2 | 2013 | 88 | 0.070 |
Why?
| | Adolescent | 2 | 2019 | 18076 | 0.060 |
Why?
| | Mitral Valve Insufficiency | 1 | 2001 | 65 | 0.060 |
Why?
| | Animals | 3 | 2014 | 34482 | 0.060 |
Why?
| | United States | 4 | 2019 | 11417 | 0.060 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 25 | 0.050 |
Why?
| | DNA Topoisomerases, Type II | 1 | 2019 | 52 | 0.050 |
Why?
| | Peptide Fragments | 2 | 2015 | 702 | 0.050 |
Why?
| | Radiotherapy Dosage | 1 | 2020 | 334 | 0.050 |
Why?
| | Societies | 1 | 2018 | 40 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2014 | 1598 | 0.050 |
Why?
| | Hemangiosarcoma | 1 | 2018 | 20 | 0.050 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2018 | 62 | 0.050 |
Why?
| | Logistic Models | 2 | 2015 | 1975 | 0.050 |
Why?
| | DNA Damage | 1 | 2020 | 355 | 0.050 |
Why?
| | Arterial Occlusive Diseases | 1 | 2018 | 84 | 0.040 |
Why?
| | Cardiovascular System | 1 | 2018 | 106 | 0.040 |
Why?
| | Interprofessional Relations | 1 | 2019 | 261 | 0.040 |
Why?
| | Reference Values | 1 | 2018 | 897 | 0.040 |
Why?
| | Morbidity | 1 | 2017 | 244 | 0.040 |
Why?
| | Program Development | 1 | 2019 | 380 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 379 | 0.040 |
Why?
| | Galectin 3 | 1 | 2015 | 15 | 0.040 |
Why?
| | Practice Guidelines as Topic | 2 | 2014 | 1542 | 0.040 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2015 | 28 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2015 | 66 | 0.040 |
Why?
| | Recurrence | 1 | 2018 | 974 | 0.040 |
Why?
| | Breast | 1 | 2015 | 136 | 0.040 |
Why?
| | Diastole | 1 | 2015 | 161 | 0.040 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 1 | 2014 | 37 | 0.040 |
Why?
| | Intraoperative Care | 1 | 2014 | 68 | 0.040 |
Why?
| | Global Health | 1 | 2017 | 320 | 0.040 |
Why?
| | Program Evaluation | 1 | 2019 | 834 | 0.040 |
Why?
| | SEER Program | 1 | 2015 | 201 | 0.040 |
Why?
| | Biopsy | 1 | 2018 | 1071 | 0.040 |
Why?
| | Ohio | 1 | 2014 | 123 | 0.040 |
Why?
| | Secondary Prevention | 1 | 2016 | 242 | 0.040 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2014 | 55 | 0.040 |
Why?
| | Europe | 1 | 2014 | 345 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2015 | 217 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2020 | 1210 | 0.030 |
Why?
| | Amyloid | 1 | 2014 | 80 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 1007 | 0.030 |
Why?
| | C-Reactive Protein | 1 | 2015 | 358 | 0.030 |
Why?
| | Acute Disease | 1 | 2016 | 986 | 0.030 |
Why?
| | Consensus | 1 | 2014 | 385 | 0.030 |
Why?
| | Interleukin-1 Receptor-Like 1 Protein | 1 | 2012 | 26 | 0.030 |
Why?
| | Odds Ratio | 1 | 2015 | 1034 | 0.030 |
Why?
| | North America | 1 | 2012 | 271 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2015 | 1208 | 0.030 |
Why?
| | Pilot Projects | 1 | 2016 | 1382 | 0.030 |
Why?
| | Radiology | 1 | 2014 | 187 | 0.030 |
Why?
| | Action Potentials | 1 | 2015 | 476 | 0.030 |
Why?
| | Disease Management | 1 | 2016 | 599 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 864 | 0.030 |
Why?
| | Time Factors | 2 | 2013 | 7090 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2012 | 570 | 0.030 |
Why?
| | Anesthesia | 1 | 2014 | 226 | 0.030 |
Why?
| | Age Factors | 1 | 2018 | 3275 | 0.030 |
Why?
| | Myocardial Contraction | 1 | 2012 | 383 | 0.030 |
Why?
| | Societies, Medical | 1 | 2014 | 757 | 0.030 |
Why?
| | Receptors, Cell Surface | 1 | 2012 | 385 | 0.030 |
Why?
| | Patient Selection | 1 | 2014 | 690 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2015 | 2607 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 2896 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 3898 | 0.020 |
Why?
| | Cohort Studies | 1 | 2013 | 4740 | 0.020 |
Why?
| | Prospective Studies | 1 | 2012 | 5904 | 0.010 |
Why?
| | Mitral Valve | 1 | 2001 | 109 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2001 | 339 | 0.010 |
Why?
| | Probability | 1 | 2001 | 336 | 0.010 |
Why?
| | Observer Variation | 1 | 2001 | 349 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2001 | 2781 | 0.010 |
Why?
|
|
Banchs's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|